← Back to Search

Behavioral Intervention

Contingency Management for Methamphetamine Use in HIV/AIDS (EXPRESS+ Trial)

N/A

Recruiting

Led By Michael J Li, PhD

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12)

Awards & highlights

EXPRESS+ Trial Summary

This trial looks at how changes in inflammation and a type of IFN expression coincide with changes in meth use and viral load in HIV-positive transgender men over 12 weeks.

Who is the study for?

This trial is for HIV-positive males aged 18-45 who have sex with men and are seeking treatment for methamphetamine use disorder. Participants must be on antiretroviral therapy, test positive for meth within 30 days before screening, and can attend bi-weekly appointments. Those using opioids, cocaine, MDMA or identifying as female cannot join.Check my eligibility

What is being tested?

The EXPRESS+ study examines if changes in stress markers align with shifts in meth use and viral load over a period of 12 weeks among HIV-positive individuals assigned male at birth who do or don't have a methamphetamine use disorder.See study design

What are the potential side effects?

Since this is a behavioral trial focusing on Contingency Management (a motivational incentive approach), it does not involve medication; therefore, typical drug side effects are not expected. However, participants may experience psychological effects due to the nature of the intervention.

EXPRESS+ Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12)

This trial's timeline: 3 weeks for screening, Varies for treatment, and once every 4 weeks over 12 weeks (i.e., baseline, week 4, week 8, week 12) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Inflammatory and Type I IFN Gene Expression over 12 weeks

Methamphetamine

Secondary outcome measures

Body Weight Changes

EXPRESS+ Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Contingency Management for Methamphetamine ReductionExperimental Treatment1 Intervention

8 weeks of contingency management, twice weekly visits, with escalating rewards from $10 to $40 for negative urine tests

Group II: Non-substance-using ControlActive Control1 Intervention

Observational visits (no intervention) at baseline, Week 4, Week 8, and Week 12 for those who do not use methamphetamine.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Contingency Management

2003

Completed Phase 2

~3220

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor

1,530 Previous Clinical Trials

10,264,653 Total Patients Enrolled

National Institute on Drug Abuse (NIDA)NIH

2,469 Previous Clinical Trials

2,619,354 Total Patients Enrolled

Michael J Li, PhDPrincipal InvestigatorUCLA Department of Family Medicine

Media Library

Contingency Management (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05558345 — N/A

Substance Use Disorders Research Study Groups: Contingency Management for Methamphetamine Reduction, Non-substance-using Control

Substance Use Disorders Clinical Trial 2023: Contingency Management Highlights & Side Effects. Trial Name: NCT05558345 — N/A

Contingency Management (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558345 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals aged 30 years and above eligible for this investigation?

"The requirements for entry into this trial state that it is only available to those aged 18-45. However, there are 132 studies for minors and 424 trials open to seniors older than 65 years old."

Answered by AI

Who is deemed eligible to enroll in this experiment?

"This medical research is admitting 55 people, aged 18 to 45, who identify as male and have been diagnosed with HIV. Crucially, these participants must be under treatment for methamphetamine use disorder while being able to attend bimonthly check-ups and drug testing sessions. Additionally, they need to fulfil the DSM-5 criteria using SCID-5 and display a positive urine test result within one month of screening visit."

Answered by AI

Is there any availability to participate in this experiment?

"Affirmative. According to clinicaltrials.gov, this medical research study is still open for enrollment. The original post appeared on September 1st 2022 and was most recently updated on the 23rd of that same month. With only one site, 55 participants are needed to complete recruitment objectives."

Answered by AI

How many individuals are being accepted to partake in this trial?

"Affirmative. The information provided on clinicaltrials.gov displays that this experiment is actively searching for participants, which was first published on September 1st 2022 and recently revised on the 23rd of the same month. This investigation requires 55 individuals from a single site to take part in it."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Expression of Stress Markers During Meth Treatment (EXPRESS+)

Michael J. Li, PhD, MPH 2022. "Expression of Stress Markers During Meth Treatment (EXPRESS+)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05558345.

All > Substance Abuse